BRPI0507746A - composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto - Google Patents

composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto

Info

Publication number
BRPI0507746A
BRPI0507746A BRPI0507746-0A BRPI0507746A BRPI0507746A BR PI0507746 A BRPI0507746 A BR PI0507746A BR PI0507746 A BRPI0507746 A BR PI0507746A BR PI0507746 A BRPI0507746 A BR PI0507746A
Authority
BR
Brazil
Prior art keywords
compound
het
solvate
salt
optionally substituted
Prior art date
Application number
BRPI0507746-0A
Other languages
English (en)
Inventor
Craig Johnstone
Darren Mckerrecher
Kurt Gordon Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34890799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507746(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0403593A external-priority patent/GB0403593D0/en
Priority claimed from GB0413386A external-priority patent/GB0413386D0/en
Priority claimed from GB0423039A external-priority patent/GB0423039D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0507746A publication Critical patent/BRPI0507746A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

COMPOSTO OU UM SAL, PRó-DROGA OU SOLVATO DO MESMO, COMPOSIçãO FARMACêUTICA, MéTODO DE TRATAR DOENçAS MEDIADAS POR GLK, E, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO em que R¬ 1¬ é metoximetila; R¬ 2¬ é selecionado de -C(O)NR¬ 4¬R¬ 5¬, -SOÐR¬ 4¬R¬ 5¬, -S(O)<sym>R¬ 4¬ e HET-2; HET-1 é um anel de heteroarila ligado por C opcionalmente substituído de 5 ou 6 membros; HET-2 é um anel de heterociclila opcionalmente substituído ligado por C ou N de 4, 5 ou 6 membros; R¬ 3¬ é selecionado de halo, fluorometila, difluorometila, trifluorometila, metila, metóxi e ciano; R¬ 4¬ é selecionado, por exemplo, de hidrogênio, alquila (1-4C) opcionalmente substituído e HET-2; R¬ 5¬ é hidrogênio ou alquila (1 -4C) ou R¬ 4¬ e R¬ 5¬juntos com o átomo de nitrogênio ao qual estão ligados podem formar um sistema de anel de heterociclila como definido por HET-3; HET-3 é, por exemplo um anel heterociclila saturado ou parcialmente insaturado de 4, 5 ou 6 membros ligado por N opcionalmente substituído; p é (independentemente de cada ocorrência) 0, 1 ou 2; m é 0 ou 1; n é 0, 1 ou 2; contanto que quando m for 0, então n será 1 ou 2 ou um sal, pró-droga ou solvato do mesmo, são descritos. Seu uso como ativadores de GLK, composições farmacêuticas que os contenham e processos para a sua preparação também são descritos.
BRPI0507746-0A 2004-02-18 2005-02-15 composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto BRPI0507746A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0403593A GB0403593D0 (en) 2004-02-18 2004-02-18 Compounds
GB0413386A GB0413386D0 (en) 2004-06-16 2004-06-16 Compounds
GB0423039A GB0423039D0 (en) 2004-10-16 2004-10-16 Compounds
PCT/GB2005/000545 WO2005080359A1 (en) 2004-02-18 2005-02-15 Benzamide derivatives and their use as glucokinae activating agents

Publications (1)

Publication Number Publication Date
BRPI0507746A true BRPI0507746A (pt) 2007-07-10

Family

ID=34890799

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507746-0A BRPI0507746A (pt) 2004-02-18 2005-02-15 composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto

Country Status (18)

Country Link
US (2) US20080280872A1 (pt)
EP (2) EP1718624B1 (pt)
JP (1) JP2007523142A (pt)
KR (1) KR20070007103A (pt)
AR (1) AR047678A1 (pt)
AT (1) ATE426597T1 (pt)
AU (1) AU2005214132B9 (pt)
BR (1) BRPI0507746A (pt)
CA (1) CA2554310A1 (pt)
DE (1) DE602005013491D1 (pt)
ES (1) ES2322709T3 (pt)
HK (1) HK1096092A1 (pt)
IL (1) IL177216A0 (pt)
NO (1) NO20063452L (pt)
RU (1) RU2392275C2 (pt)
TW (1) TW200602028A (pt)
UY (1) UY28756A1 (pt)
WO (1) WO2005080359A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2004081001A1 (ja) 2003-02-13 2004-09-23 Banyu Pharmaceutical Co., Ltd. 新規２－ピリジンカルボキサミド誘導体
MXPA05009059A (es) 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
CA2554310A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Benzamide derivatives and their use as glucokinase activating agents
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423042D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Chemical process
JP2008516935A (ja) * 2004-10-16 2008-05-22 アストラゼネカ アクチボラグ フェノキシベンズアミド化合物の製造方法
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
BRPI0613570B8 (pt) * 2005-07-09 2021-05-25 Astrazeneca Ab composto, composição farmacêutica e uso de um composto ou um sal farmaceuticamente aceitável do mesmo
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
AU2007278261A1 (en) 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
CL2007003061A1 (es) * 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
AR064625A1 (es) * 2006-12-21 2009-04-15 Astrazeneca Ab Forma cristalina de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-[(1-metiletil)oxi]-n-1h-pirazol-3-ilbenzamida
EP2173717B9 (en) 2007-07-27 2013-06-26 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
JP5457358B2 (ja) 2007-10-09 2014-04-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコキナーゼアクチベーターとしてのｎ−（ピラゾール−３−イル）−ベンズアミド誘導体
PL2239253T3 (pl) 2008-02-06 2013-11-29 Daiichi Sankyo Co Ltd Nowe pochodne fenylopirolowe
EA201001367A1 (ru) * 2008-02-27 2011-04-29 Мерк Патент Гмбх Производные карбоксамид-гетероарила для лечения диабета
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
BRPI0917589A2 (pt) 2008-08-04 2015-11-17 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, método para tratar doenças, processo, combinação farmacêutica, e, reação de metiloxirano-2-carboxilato (ix) com um álcool roh
WO2010082601A1 (ja) * 2009-01-16 2010-07-22 第一三共株式会社 新規２，５－二置換ピロール誘導体
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
JPWO2010128595A1 (ja) * 2009-05-07 2012-11-01 富士フイルムＲｉファーマ株式会社 放射性ヨウ素標識イミダゾピリジン誘導体の製造法
US8450494B2 (en) 2009-06-22 2013-05-28 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (GK) activators
KR20120047960A (ko) 2009-07-31 2012-05-14 카딜라 핼쓰캐어 리미티드 글루코키나아제(ｇｋ) 활성화제로서 치환된 벤즈아미드 유도체
WO2011071095A1 (ja) * 2009-12-11 2011-06-16 アステラス製薬株式会社 ベンズアミド化合物
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
WO2011122458A1 (ja) * 2010-03-29 2011-10-06 第一三共株式会社 含窒素芳香環化合物

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2750393A (en) * 1954-12-01 1956-06-12 Sterling Drug Inc Iodinated 5-henzamidotetrazoles and preparation thereof
US2967194A (en) * 1958-05-15 1961-01-03 Pennsalt Chemicals Corp 4-trifluoromethylsalicylamides
GB1400540A (en) * 1972-12-06 1975-07-16 Smith Kline French Lab Salicylamides and compositions thereof
US4009174A (en) * 1972-12-08 1977-02-22 The Boots Company Limited Esters of substituted nicotinic acids
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1561350A (en) * 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
FR2344284A1 (fr) * 1976-03-17 1977-10-14 Cerm Cent Europ Rech Mauvernay Nouveaux composes tricycliques a cycle furannique et leur application comme antidepresseurs
US4474792A (en) * 1979-06-18 1984-10-02 Riker Laboratories, Inc. N-Tetrazolyl benzamides and anti-allergic use thereof
FR2493848B2 (fr) * 1980-11-07 1986-05-16 Delalande Sa Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique
JPS59139357A (ja) * 1983-01-28 1984-08-10 Torii Yakuhin Kk アミジン誘導体
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
US5466715A (en) * 1991-12-31 1995-11-14 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5258407A (en) * 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5273986A (en) * 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
US5661153A (en) * 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
US5510478A (en) * 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5672750A (en) * 1994-12-16 1997-09-30 Eastman Chemical Company Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride
US5849735A (en) * 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5712270A (en) * 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
TW429241B (en) 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
AUPO395396A0 (en) * 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
FR2757852B1 (fr) * 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
EP0995742A4 (en) * 1997-06-27 2004-08-25 Fujisawa Pharmaceutical Co SULPHONAMIDE COMPOUNDS AND THEIR MEDICAL USE
ES2229510T3 (es) * 1997-06-27 2005-04-16 Fujisawa Pharmaceutical Co., Ltd. Derivados de anillo aromatico.
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP1053227B1 (en) * 1998-01-29 2008-11-05 Amgen Inc. Ppar-gamma modulators
DE19816780A1 (de) * 1998-04-16 1999-10-21 Bayer Ag Substituierte 2-Oxo-alkansäure-[2-(indol-3-yl)-ethyl]amide
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6197798B1 (en) * 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
RU2242469C2 (ru) * 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
RS50045B (sr) 1999-03-29 2008-11-28 F.Hoffmann-La Roche Ag., Aktivatori glukokinaze
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
AU1917201A (en) * 1999-11-18 2001-05-30 Centaur Pharmaceuticals, Inc. Amide therapeutics and methods for treating inflammatory bowel disease
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
ES2254385T3 (es) * 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
EP1282612B1 (en) * 2000-05-03 2004-12-29 F. Hoffmann-La Roche Ag Alkynyl phenyl heteroaromatic glucokinase activators
ATE323071T1 (de) * 2000-11-22 2006-04-15 Astellas Pharma Inc Substituierte phenolderivate und deren salze als hemmstoffe von koagulations faktor x
KR100545431B1 (ko) * 2000-12-06 2006-01-24 에프. 호프만-라 로슈 아게 축합된 이종방향족 글루코키나제 활성화제
CN1289072C (zh) * 2000-12-22 2006-12-13 石原产业株式会社 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
EP1431267A4 (en) * 2001-08-09 2004-12-22 Ono Pharmaceutical Co COMPOUNDS DERIVED FROM CARBOXYLIC ACID AND MEDICAMENTS COMPRISING SUCH COMPOUNDS AS ACTIVE INGREDIENT
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
DE10161765A1 (de) * 2001-12-15 2003-07-03 Bayer Cropscience Gmbh Substituierte Phenylderivate
KR101018318B1 (ko) 2001-12-21 2011-03-04 노보 노르디스크 에이/에스 Ｇｋ 활성제로서의 아미드 유도체
CA2488161A1 (en) * 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
BR0309546A (pt) 2002-04-26 2005-02-15 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
EP1531815B1 (en) 2002-06-27 2014-09-24 Novo Nordisk A/S Glucokinase activators
WO2004007472A1 (ja) * 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ｃｃｒ４アンタゴニストおよびその医薬用途
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MXPA05009059A (es) 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
WO2005048953A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
GB0327760D0 (en) * 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0327761D0 (en) * 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
CA2554310A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Benzamide derivatives and their use as glucokinase activating agents
AU2005214137B2 (en) * 2004-02-18 2008-05-29 Astrazeneca Ab Compounds
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
US8143404B2 (en) * 2004-09-13 2012-03-27 Ono Pharmaceutical Co., Ltd Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient
JP2008516935A (ja) * 2004-10-16 2008-05-22 アストラゼネカ アクチボラグ フェノキシベンズアミド化合物の製造方法
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
BRPI0613570B8 (pt) * 2005-07-09 2021-05-25 Astrazeneca Ab composto, composição farmacêutica e uso de um composto ou um sal farmaceuticamente aceitável do mesmo
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
JP2009508832A (ja) * 2005-09-16 2009-03-05 アストラゼネカ アクチボラグ グルコキナーゼ活性化剤としてのヘテロ二環式化合物
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (es) * 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
AR064625A1 (es) * 2006-12-21 2009-04-15 Astrazeneca Ab Forma cristalina de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-[(1-metiletil)oxi]-n-1h-pirazol-3-ilbenzamida

Also Published As

Publication number Publication date
EP1718624B1 (en) 2009-03-25
NO20063452L (no) 2006-10-31
EP1718624A1 (en) 2006-11-08
UY28756A1 (es) 2005-09-30
ES2322709T3 (es) 2009-06-25
US20080280872A1 (en) 2008-11-13
RU2392275C2 (ru) 2010-06-20
ATE426597T1 (de) 2009-04-15
EP2048137A1 (en) 2009-04-15
TW200602028A (en) 2006-01-16
CA2554310A1 (en) 2005-09-01
KR20070007103A (ko) 2007-01-12
AR047678A1 (es) 2006-02-01
HK1096092A1 (en) 2007-05-25
JP2007523142A (ja) 2007-08-16
AU2005214132A1 (en) 2005-09-01
IL177216A0 (en) 2006-12-10
WO2005080359A1 (en) 2005-09-01
DE602005013491D1 (de) 2009-05-07
AU2005214132B9 (en) 2009-06-25
US20110034432A1 (en) 2011-02-10
AU2005214132B2 (en) 2009-05-07
RU2006130684A (ru) 2008-03-27

Similar Documents

Publication Publication Date Title
BRPI0507746A (pt) composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
BRPI0507734A (pt) composto ou um sal, pró-droga ou solvato do mesmo, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
BRPI0511808A (pt) composto ou um sal, pró-droga ou solvato do mesmo, uso de um composto método para tratar doenças mediadas com glk, e, processo para a preparação de um composto
AR074238A1 (es) Compuesto de n-{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4,1.0]hept-4-il]metil}-2-heteroarilamina, su uso para la preparacion de un medicamento util para el tratamiento de una enfermedad que requiere un antagonista del receptor de orexina humano y composicion farmaceutica que lo comprende
BR0110240A (pt) Composto, processo para a preparação de um composto, processo para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
BR112015018882A2 (pt) derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo
BRPI0714665A2 (pt) Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer
CY1109568T1 (el) Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων
BRPI0607600A2 (pt) derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
BRPI0511554A (pt) composto ou um sal ou pró-droga farmaceuticamente aceitável do mesmo, método para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto ou de um sal farmaceuticamente aceitável, ou de um éster hidrolisável in vivo do mesmo, composição farmacêutica, e, processo para a preparação de um composto ou de um sal farmaceuticamente aceitável, ou de um éster hidrolisável in vivo do mesmo
BR112015025729A2 (pt) métodos para dividir e para produzir um composto, composto, composição farmacêutica, agente profilático ou terapêutico, e, uso de um cristal
BRPI0820779B8 (pt) compostos derivados de 4-amino-pirimidina, composição farmacêutica, uso e processo para preparação dos referidos compostos
ATE386031T1 (de) Benzoylaminopyridylcarbonsäurederivate als glucokinaseaktivatoren
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
MX2016001519A (es) Derivados de 25-oh vitamina d para determinacion de metabolitos de vitamina d.
DK1893589T3 (da) Substituerede N-benzo[d]isoxazol-3-yl-amin-derivater som inhibitorer af mGluR5-, serotonin-(5-HT) og noradrenalinreceptorer og deres anvendelse til fremstilling af lægemidler
Wang et al. Synthesis of C2-functionalized pyrimidines from 3, 4-dihydropyrimidin-2 (1H)-ones by the Mitsunobu coupling reaction
BR112018072063A2 (pt) compostos de pirimidinona fundida substituída
UA87685C2 (ru) Производные гетероарилбензамида для применения как активаторов glk в лечении диабета
BR112023021429A2 (pt) Inibidores de proteína quinase dependente de dna e composições e usos dos mesmos
EA200970426A1 (ru) Селективный агонист tr-бета 1
BR0308223A (pt) Derivados de piridiniloxi como ligantes de receptor 5-ht
DE602007008748D1 (de) Fluorierte catharanthinderivate, ihre herstellung und ihre verwendung als dimere vorstufen für vincaalkaloide

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE, CONFORME ART. 10 DA RES. 124/06.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.